Skip to Main Content Menu Search Site

Metabolically Labeled CAR-T Cells Against Cancer

Patient-derived T cells carrying immune-enhancing cytokines on their surfaces through simple and effective approach could help expand adoptive T cell therapies to treatment of solid tumors

Interested in helping de-risk and commercialize metabolic T cell labeling?

The team is currently seeking additional funding sources, as well as industry and academic collaborators to validate this technology’s aspects and applications.



Key Features
  • Cytokine enhancement of therapeutic T cells before their adoptive transfer to recipients with solid and hard-to-treat blood cancers
  • Novel metabolic labeling technology that engineers T cells’ surface sugars as targets for cytokine attachments
  • Simple and readily integrated with current manufacturing process for therapeutic T cells
Close menu